Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology
Standard
Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. / Reiswich, Viktor; Akdeniz, Gonca; Lennartz, Maximilian; Menz, Anne; Chirico, Viktoria; Hube-Magg, Claudia; Fraune, Christoph; Bernreuther, Christian; Simon, Ronald; Clauditz, Till S; Sauter, Guido; Uhlig, Ria; Hinsch, Andrea; Kind, Simon; Jacobsen, Frank; Möller, Katharina; Steurer, Stefan; Minner, Sarah; Burandt, Eike; Marx, Andreas H; Lebok, Patrick; Krech, Till; Dum, David.
In: HUM PATHOL, Vol. 126, 08.2022, p. 108-120.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology
AU - Reiswich, Viktor
AU - Akdeniz, Gonca
AU - Lennartz, Maximilian
AU - Menz, Anne
AU - Chirico, Viktoria
AU - Hube-Magg, Claudia
AU - Fraune, Christoph
AU - Bernreuther, Christian
AU - Simon, Ronald
AU - Clauditz, Till S
AU - Sauter, Guido
AU - Uhlig, Ria
AU - Hinsch, Andrea
AU - Kind, Simon
AU - Jacobsen, Frank
AU - Möller, Katharina
AU - Steurer, Stefan
AU - Minner, Sarah
AU - Burandt, Eike
AU - Marx, Andreas H
AU - Lebok, Patrick
AU - Krech, Till
AU - Dum, David
N1 - Copyright © 2022. Published by Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Uroplakin 1B (Upk1b) stabilizes epithelial cells lining the bladder lumen to prevent rupturing during bladder distension. Little is known about Upk1b expression in other normal and malignant tissues. To comprehensively evaluate the potential diagnostic and prognostic utility of Upk1b expression analysis, a tissue microarray containing 14,061 samples from 127 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Upk1b immunostaining was found in 61 (48%) different tumor types including 50 (39%) with at least one moderately positive and 39 tumor types (31%) with at least one strongly positive tumor. Highest positivity rates were found in urothelial neoplasms (58-95%), Brenner tumors of the ovary (92%), epithelioid mesothelioma (87%), serous carcinoma of the ovary (58%) and the endometrium (53%) as well as in squamous cell carcinoma of the head and neck (18-37%), lung (39%), and esophagus (26%). In urothelial carcinoma, low Upk1b expression was linked to high grade and invasive tumor growth (P < .0001 each) and nodal metastasis (P = .0006). Our data suggest diagnostic applications of Upk1b immunohistochemistry in panels for the distinction of malignant mesothelioma from adenocarcinoma of the lung, urothelial carcinoma from prostatic adenocarcinoma in the bladder, or pancreaticobiliary and gastroesophageal from colorectal adenocarcinoma.
AB - Uroplakin 1B (Upk1b) stabilizes epithelial cells lining the bladder lumen to prevent rupturing during bladder distension. Little is known about Upk1b expression in other normal and malignant tissues. To comprehensively evaluate the potential diagnostic and prognostic utility of Upk1b expression analysis, a tissue microarray containing 14,061 samples from 127 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Upk1b immunostaining was found in 61 (48%) different tumor types including 50 (39%) with at least one moderately positive and 39 tumor types (31%) with at least one strongly positive tumor. Highest positivity rates were found in urothelial neoplasms (58-95%), Brenner tumors of the ovary (92%), epithelioid mesothelioma (87%), serous carcinoma of the ovary (58%) and the endometrium (53%) as well as in squamous cell carcinoma of the head and neck (18-37%), lung (39%), and esophagus (26%). In urothelial carcinoma, low Upk1b expression was linked to high grade and invasive tumor growth (P < .0001 each) and nodal metastasis (P = .0006). Our data suggest diagnostic applications of Upk1b immunohistochemistry in panels for the distinction of malignant mesothelioma from adenocarcinoma of the lung, urothelial carcinoma from prostatic adenocarcinoma in the bladder, or pancreaticobiliary and gastroesophageal from colorectal adenocarcinoma.
U2 - 10.1016/j.humpath.2022.05.002
DO - 10.1016/j.humpath.2022.05.002
M3 - SCORING: Journal article
C2 - 35550834
VL - 126
SP - 108
EP - 120
JO - HUM PATHOL
JF - HUM PATHOL
SN - 0046-8177
ER -